ArticleInternational journal of radiation oncology, biology, physics2025
Once-Daily Postmastectomy Radiation Therapy Confers Excellent Locoregional Control for Inflammatory Breast Cancer.
Article in International journal of radiation oncology, biology, physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Case of Neoadjuvant Chemotherapy for Locally Advanced Inflammatory Breast Cancer With Low-Level ER Expression.Case reports in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeFor patients with cT4dM0 inflammatory breast cancer (IBC), improved locoregional control has been reported following modern trimodality therapy that includes hyperfractionated/twice-daily postmastectomy radiation therapy (PMRT). We evaluated survival outcomes in a contemporary cohort of patients with IBC routinely treated with once-daily PMRT. METHODS AND MATERIALS: We retrospectively identified 213 patients with stage III IBC treated with neoadjuvant systemic therapy, modified radical mastectomy, and PMRT from January 2006 to December 2022 at a single institution. Routinely, PMRT included 50 Gy in 18 to 25 daily fractions to the chest wall and regional nodes with a 0.5 to 1.0 cm skin bolus. We calculated the crude rate of isolated locoregional recurrence (LRR) and estimated disease-free survival (DFS) rates using Kaplan-Meier survival curves and a Cox proportional hazard regression model.
resultsMedian follow-up was 3.5 years (IQR, 1.8-6.3 years). Isolated LRR was observed in 1.8% (4/213) of patients at a median of 10.6 months (IQR, 8.8-18.4 months). LRR with or without a distant failure occurred in 22 patients (10.3%). All LRRs were observed in patients who did not achieve pathologic complete response (pCR) (n = 148). Distant metastasis occurred in 32% (69/213) of patients, and 57 deaths were recorded. On multivariable analysis, triple-negative subtype (hazard ratio [HR], 3.16; 95% CI, 1.56-6.41; P = .001), lobular histology (HR, 2.45; 95% CI, 1.10-5.45; P = .027), and nodal pCR (HR, 0.27; 95% CI, 0.15-0.49; P < .001) were associated with DFS rates. Subgroup analysis demonstrated no difference in DFS rates between biologic subtypes in patients with pCR (P = .29).
conclusionsOnce-daily PMRT confers excellent locoregional control in patients with IBC, as evidenced by low rates of isolated LRR at 3.5 years of follow-up. The worse overall LRR and DFS rates observed in patients with triple-negative subtype and residual nodal disease indicate a need to consider escalating local therapy with a boost while also emphasizing the necessity for novel systemic therapies for IBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.